Search results
FY2026 EPS Estimates for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reduced by HC Wainwright
ETF DAILY NEWS· 2 days agoRigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) – Equities researchers at HC Wainwright cut their FY2026 EPS estimates for Rigel Pharmaceuticals in a research report issued on Wednesday ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days ago– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoPomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton ...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 7 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...
BNP Paribas Financial Markets Acquires 26,818 Shares of Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 1 day agoBNP Paribas Financial Markets boosted its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 9.7% during the fourth quarter, according to the company in its most recent filing with ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoVincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health
Brokerages Set Incyte Co. (NASDAQ:INCY) PT at $74.93
ETF DAILY NEWS· 5 days agoIncyte Co. (NASDAQ:INCY – Get Free Report) has been given an average recommendation of “Hold” by the seventeen research firms that are covering the company, Marketbeat reports. Nine equities ...
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's...
Digital Journal· 3 days agoSTONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion ...
Metis Global Partners LLC Sells 549 Shares of Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 5 days agoMetis Global Partners LLC lessened its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned ...
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s...
The Kansas City Star· 3 days agoSTONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion ...